BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

PURPOSE: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and nat...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Woyach, Jennifer A., Ruppert, Amy S., Guinn, Daphne, Lehman, Amy, Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2017
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455463/
https://ncbi.nlm.nih.gov/pubmed/28418267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.2282
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料